Features | Partner Sites | Information | LinkXpress
Sign In

Nasal Bacteria Could Predict Skin Infections

By Labmedica International staff writers
Posted on 05 Jun 2014
Image: Scanning electron micrograph of Methicillin-resistant Staphylococcus aureus and a dead human neutrophil (Photo courtesy of the US National Institute of Allergy and Infectious Diseases).
Image: Scanning electron micrograph of Methicillin-resistant Staphylococcus aureus and a dead human neutrophil (Photo courtesy of the US National Institute of Allergy and Infectious Diseases).
Bacteria found in the nose may be a key indicator for future development of skin and soft-tissue infections in remote areas of the body.

The nose is the primary reservoir of Staphylococcus aureus in humans and in nearly 80% of the cases, an individual's colonizing strain is the same strain that causes subsequent remote skin infections. However, until now, no one has been able to determine why some S. aureus carriers develop infections while others do not.

Scientist at the Uniformed Services University of the Health Sciences (Bethesda, MD, USA) postulated that the population of S. aureus in an individual's nose may harbor valuable clues regarding skin and soft tissue infections (SSTI) susceptibility that had not yet been described. This is of particular interest to the military, as it is well known that soldiers in training are at increased risk of developing an SSTI. They collected nasal samples and cultures from 86 infantry soldiers and for those individuals among the 86 who developed SSTIs, the investigators also collected samples and cultures from within the soldiers' skin abscesses.

The team used a high-throughput DNA sequencing strategy to determine the microbial composition of each sample. The biodiversity of the bacterial population in each nose was compared between individuals colonized and/or infected with Methicillin-Resistant S. aureus (MRSA), Methicillin-Sensitive S. aureus (MSSA), and those individuals that were culture-negative for S. aureus.

The scientists observed a significantly higher percentage of a type of bacteria known as Proteobacteria in the noses of individuals who did not develop SSTI, suggesting that Proteobacteria may, in fact, be protective against the development of SSTIs. Furthermore, S. aureus carriers had a unique nasal microbiome that differed from non-carriers. The Proteobacteria are a major phylum of bacteria. They include a wide variety of pathogens, such as Escherichia, Salmonella, Vibrio, Helicobacter, and many other notable genera.

The scientists concluded that by establishing a nose marker microbiome associated with development of SSTI infections may pave the way for focused preventive treatments that target the microbiome, rather than S. aureus itself. They believe that this study will aid in the design of future prophylactic procedures that can help prevent SSTI, particularly in the setting of military training, and help influence how health care providers think about and treat these complex and diverse infections. The study was presented at the 114th General Meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).

Related Links:

Uniformed Services University of the Health Sciences

Sekisui Diagnostics
comments powered by Disqus
Life Technologies


Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more


view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image: The ADVIA Centaur XPT Immunoassay System delivers the results that clinicians depend upon for accurate diagnoses and better patient care (Photo courtesy of Siemens Healthcare).

Introduction of New Central Laboratory Clinical Analyzers Highlights Recent Lab Equipment Exposition

An impressive array of new automated analyzers for central diagnostic laboratories was unveiled at a recent lab equipment trade fair. The IFCC WorldLab exposition held June 22-26, 2014, in Istanbul... Read more

Industry News

view channel

Beckman Coulter Acquires Siemens Healthcare Diagnostics’ Clinical Microbiology Business

Beckman Coulter (Brea, CA, USA), an indirect wholly-owned subsidiary of Danaher Corp. (Washington DC, MD, USA) has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (Chicago, IL, USA). The transaction is expected to close in the first quarter of 2015.... Read more
Copyright © 2000-2014 Globetech Media. All rights reserved.